Ikena Oncology to Participate in Cowen 43rd Annual Health Care Conference
February 28, 2023 08:00 ET
|
Ikena Oncology, Inc.
BOSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that...
Ikena Oncology Appoints Owen Hughes as Board Chair
December 19, 2022 16:30 ET
|
Ikena Oncology, Inc.
Owen Hughes joins Ikena Board as independent director with operational and public company experience Ron Renaud steps down as he transitions into investment management role BOSTON,...
Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update
November 28, 2022 08:00 ET
|
Ikena Oncology, Inc.
Novel best-in-class MEK-RAF complex inhibitor IK-595 targets RAS pathway; IND in 2023 Novel paralog-selective TEAD inhibitor IK-930 advancing as planned in dose escalation; clinical data in 2023 ...
Ikena Oncology to Participate in the Piper Sandler 34th Annual Healthcare Conference
November 22, 2022 07:30 ET
|
Ikena Oncology, Inc.
BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that...
Ikena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma
November 10, 2022 09:00 ET
|
Ikena Oncology, Inc.
IK-175 combined with nivolumab showed durable antitumor activity with a 20% ORR and 40% DCR in heavily pretreated urothelial carcinoma IK-175 monotherapy activity observed; confirmed partial response...
UPDATE -- Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
November 07, 2022 08:48 ET
|
Ikena Oncology, Inc.
Initial clinical data of AHR antagonist, IK-175, shows treatment is well-tolerated and demonstrates anti-tumor activity both as a monotherapy and in combination with nivolumab IK-930, lead targeted...
Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
November 07, 2022 08:05 ET
|
Ikena Oncology, Inc.
Initial clinical data of AHR antagonist, IK-175, shows treatment is well-tolerated and demonstrates anti-tumor activity both as a monotherapy and in combination with nivolumab Progressing lead...
Ikena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combating Therapeutic Resistance
October 26, 2022 07:30 ET
|
Ikena Oncology, Inc.
BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced a...
Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway
October 18, 2022 07:30 ET
|
Ikena Oncology, Inc.
Clinical collaboration with AstraZeneca announced for the evaluation of osimertinib in combination with IK-930 for patients with EGFR-mutant lung cancers Company shares further detail on the...
Ikena Oncology to Present Initial Phase 1a/b Results from Novel AHR Inhibition Program at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
October 05, 2022 08:05 ET
|
Ikena Oncology, Inc.
BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that...